7 Aug 2019 11:04
7 August 2019
Â
Diurnal Group plc
("Diurnal" or the "Company")
Â
Director Dealings
Â
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' dealings undertaken for tax planning purposes:
Â
Martin Whitaker, Chief Executive Officer, sold 44,810 Ordinary Shares at a price of 37 pence per Ordinary Share and his ISA purchased 44,810 Ordinary Shares at a price of 37.1 pence per Ordinary Share.
Â
Additionally, Martin Whitaker purchased a total of 15,104 Ordinary Shares at 38 pence per share, to be held in pension schemes for the beneficial interest of his dependent children.
Â
Following the transactions, the total beneficial interest of Martin Whitaker and his connected parties is 120,643 Ordinary Shares, representing 0.14% of the total voting rights.
Â
Details of the full notifications received by the Company are set out below:
Â
1  | Details of the person discharging managerial responsibilities / person closely associated  | ||||
a)  | Name  |  Martin Whitaker | |||
2  | Reason for the notification  | ||||
a)  | Position/status  | Chief Executive Officer | |||
b)  | Initial notification /Amendment  | Initial notification | |||
3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  | ||||
a)  | Name  | Diurnal Group plc | |||
b) Â | LEI Â | 213800I2HNUNZN1LDH29 | |||
4  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  | ||||
a) Â | Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)  | Nature of the transaction  | Sale and purchase of ordinary shares  | |||
c) Â | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
Sell 37p Purchase 37.1p | 44,810 44,810 | Â Â | |||
d) Â | Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price | |||||
e)  | Date of the transaction  | 6 August 2019 | |||
f)  | Place of the transaction  | XLON | |||
Â
Â
1  | Details of the person discharging managerial responsibilities / person closely associated  | ||||
a)  | Name  |  Martin Whitaker and dependent children | |||
2  | Reason for the notification  | ||||
a)  | Position/status  | Chief Executive Officer | |||
b)  | Initial notification /Amendment  | Initial notification | |||
3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  | ||||
a)  | Name  | Diurnal Group plc | |||
b) Â | LEI Â | 213800I2HNUNZN1LDH29 | |||
4  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  | ||||
a) Â | Description of the financial instrument, type of instrument | Ordinary shares of 5 pence each in Diurnal Group plc | |||
Identification code | GB00BDB6Q760 | ||||
b)  | Nature of the transaction  | Purchase of ordinary shares for the beneficial interest of his children  | |||
c) Â | Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
Buy 38p | 15,104 | ||||
d) Â | Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price | |||||
e)  | Date of the transaction  | 7 August 2019 | |||
f)  | Place of the transaction  | XLON | |||
Â
Â
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl | |
Corporate Broking: James Stearns | |
Cantor Fitzgerald Europe (Joint Broker) | +44 (0)20 7894 7000 |
Corporate Finance: Phil Davies, Will Goode, Michael Boot | |
Healthcare Equity Sales: Andrew Keith | |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Â
Notes to Editors
Â
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
Â
For further information about Diurnal, please visit www.diurnal.co.uk